• Provided strategic guidance, resulting in improved operational efficiency and alignment with organizational goals.• Directed financial oversight, leading to a 63% average annual percentage growth rate while maintaining full compliance with regulatory frameworks.• Represented Ipsum Clinical in high-profile stakeholder meetings, successfully securing new clinical trial partnerships with major pharma companies.• Advised on strategic decisions regarding site acquisition and new trials.

• Led the development and certification of 6 clinical trial sites through strategic joint ventures with hospitals and clinics.• Provide leadership and experience in the planning, implementation, and execution of clinical studies.• Ensure all clinical studies are conducted in accordance with company SOPs, GCPs and ICH guidelines.• Collaborated with cross-functional teams to successfully implement clinical strategic plans, increasing operational efficiency by 20% and accelerating trial timelines.Examples of some studies I have worked on:Bayer AG, Leverkusen:Study of a pediatric nifurtimox formulation for Chagas disease.Merck Sharp & Dohme Corp:Chronic cough in adults (MK-7264)Teva Branded Pharmaceutical Products R&D, Inc.:Tourette's syndrome (ST) (TEV-50717)Janssen Research & Development, LLC:Active Systemic Lupus Erythematosus (Ustekinumab)Merck Sharp & Dohme Corp:Premature infants (MK-1654)Daiichi Sankyo, Inc.Pediatric subjects with venous thromboembolism (Edoxaban)AstraZeneca PLCInfants entering their first RSV season (MEDI8897)Esperion Therapeutics, Inc.Patients with cardiovascular disease (Bempedoic acid, ETC-1002)AbbVie Inc.Moderate to Severe Atopic Dermatitis (Upadacitinib)CSL Behring LLCAcute coronary syndrome (CSL112)GlaxoSmithKline Biologicals SAPregnancy outcomes and incidence in infants of RSVNovartisSacubitril/valsartan compared with enalapril in patients with Chagas cardiomyopathyPfizerCardiovascular Risk Factors and Treatment in General Practice PatientsSanofi Aventis Group, SAGAdult atopic dermatitis patientsHamilton Health Sciences through Population Health Research InstituteCongestive Heart Failure (G‐CHF)AmgenClinical characteristics of subjects prior to initiation of RepathaGeneOneZika IgM assay to detect incident Zika virus infectionWHOImmunogenicity of Inactivated Poliovirus Vaccine (IPV)Johnson & JohnsonCOVID-19 vaccine (VAC31518COV3001)

Strategic Fundraising:• Executed strategic fundraising initiatives to secure financial support for the Marine Foundation's mission. For example, secured $200k funding from a donor by utilizing a robust global network, demonstrating exceptional fundraising acumen.• Implemented innovative fundraising campaigns that effectively communicated the foundation's goals and garnered positive attention.Stakeholder Engagement:• Established and nurtured relationships with key stakeholders, including donors, partners, and community leaders, fostering a collaborative network of support.• Conducted presentations and engagement activities to effectively communicate the foundation's vision and initiatives.

• Developed Jordan Red, the top-ranking bull worldwide, generating $1.5M in revenue through global semen sales in 51 countries, solidifying the brand’s global presence.• Boosted market share in 15 countries by implementing a data-driven marketing strategy, leading to a 35% increase in revenue and expanding into three new regions.• Drove international sales and marketing efforts, leading to strong growth in product distribution, and cultivated key partnerships with leading industry players.

• Conducted comprehensive market analysis across Latin America, identifying untapped opportunities leading to market penetration in the region.• Improved product innovation and market expansion, opening 5 new markets in Latin America.• Negotiated and closed contracts worth $1M across Latin American markets, ensuring long-term partnerships and resolving contractual disputes.• Making deals, negotiating contracts, managing conflictshttp://www.abcgenetics.com/

• Established and operationalized a new clinical trial site, enabling participation in over 10 trials within the first 2 years.Examples of some studies I have worked on:Merck Sharp & DohmeSPIRO:A 26-week randomized, double-blinded, active controlled study comparing the safety of mometasone furoate/formoterol fumarate MDI fixed dose combination versus mometasone furoate MDI monotherapy in adolescents and adults with persistent asthma.BPL (Bio Products Laboratory Ltd)OPTIVE:Multicentre, non-controlled, prospective, post-marketing safety study following long-term prophylactic Optivate® treatment in subjects with severe haemophilia A.Janson & JansonMARINER:Global trial to evaluate prophylactic safety and efficacy of extended treatment with an orally administered anticoagulant, rivaroxaban, in high risk medically ill patients for the prevention of venous thromboembolic events (VTE), including pulmonary embolism (PE). TrombosisJanson & JansonCREDENCE:(Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation)Randomized, double-blind, event-driven, placebo-controlled, multicenter study of the effects of Canagliflozin on renal and cardiovascular outcomes in subjects with type 2 diabetes mellitus and diabetic nephropathy.

Development of crops with higher resistance to diseases